Ann: CEO's address to AGM , page-3

So the bad news is Intrepid trials are running 6 months behind.

They are bringing on new sites.


The Good news is

"On a positive note, the incidence of serious adverse events or SAEs continues to be very
low as does mortality. We recently completed the reproductive toxicology studies that are necessary
to initiate a pivotal trial and found no effects whatsoever on male or female fertility or reproductive
fitness."

So does the Serious adverse events and low mortality, have a statistically significant result which makes NNZ-2566 approveable.

I imagine somebody at the AGM has got a definitive answer to that question.

I like a punt, so I would back it in that this will eventually be an approved drug.

At these prices the odds are too heavily stacked my way not to have a decent punt.